MedPath

SyneuRx International (Taiwan) Corp.

🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website

Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19

Phase 2
Conditions
Coronavirus Disease 2019
Interventions
Drug: Pentarlandir™ UPPTA
Drug: Placebo
First Posted Date
2021-06-03
Last Posted Date
2021-12-17
Lead Sponsor
SyneuRx International (Taiwan) Corp
Target Recruit Count
90
Registration Number
NCT04911777
Locations
🇺🇸

Eminat Research Group, Plantation, Florida, United States

🇺🇸

Elite Medical Research, Dallas, Texas, United States

🇺🇸

Accurate Clinical Research, Houston, Texas, United States

and more 9 locations

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

Phase 2
Recruiting
Conditions
Refractory Schizophrenia
Interventions
Other: Placebo
First Posted Date
2017-03-29
Last Posted Date
2021-09-13
Lead Sponsor
SyneuRx International (Taiwan) Corp
Target Recruit Count
287
Registration Number
NCT03094429
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact SyneuRx International Corp., Pasadena, California, United States

Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults

Phase 2
Terminated
Conditions
Schizophrenia
Interventions
Other: Placebo
First Posted Date
2014-10-10
Last Posted Date
2024-05-24
Lead Sponsor
SyneuRx International (Taiwan) Corp
Target Recruit Count
280
Registration Number
NCT02261519
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact SyneuRx International Corp., Pasadena, California, United States

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Phase 2
Terminated
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2013-07-25
Last Posted Date
2024-05-09
Lead Sponsor
SyneuRx International (Taiwan) Corp
Target Recruit Count
60
Registration Number
NCT01908192
Locations
🇺🇸

John Hopkins University - Hugo W Moser Research Institute at Kennedy Krieger Inc., Baltimore, Maryland, United States

🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

🇺🇸

Premier Clinical Research Institute, Miami, Florida, United States

and more 19 locations
© Copyright 2025. All Rights Reserved by MedPath